# Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

> **NCT02735239** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 73 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Leucovorin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02735239
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-24
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735239, "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02735239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*